Repositorio Institucional de la Universidad de Oviedo

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial

Autor(es) y otros:

Vansteenkiste, Johan F.; Cho, Byoung Chul; Vanakesa, Tonu; Esteban González, Emilio

Fecha de publicación:

2016

Versión del editor:

http://dx.doi.org/10.1016/S1470-2045(16)00099-1

Citación:

Lancet Oncology, 17(6), p. 822-835 (2016); doi:10.1016/S1470-2045(16)00099-1

Descripción física:

p. 822-835

URI:

http://hdl.handle.net/10651/39536

ISSN:

1470-2045; 1474-5488

DOI:

10.1016/S1470-2045(16)00099-1

Patrocinado por:

GlaxoSmithKline

This study was designed, funded, and interpreted by GlaxoSmithKline in cooperation with an international steering committee